Diagnosing asthma and chronic obstructive pulmonary disease

Gupta, Samir

doi:10.46747/cfp.6806441

Cited by 27 publications

(39 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Glaucoma is correlated with an increase in intraocular pressure, leading to irreversible damage of the optic nerve. In most cases, the disease onset causes no symptoms, which is the reason why it is often called "the silent thief of sight" (Gupta & Chen, 2016). As in the case of other eye diseases, nowadays there is no cure for glaucoma, but pharmaceutical and surgical treatments that can stop the progressive vision loss.…”

Section: Biomarker Discovery In Ophthalmologymentioning

confidence: 99%

Mass spectrometry‐based tear proteomics for noninvasive biomarker discovery

Ponzini

Santambrogio

Palma

et al. 2021

Mass Spectrometry Reviews

View full text Add to dashboard Cite

The lacrimal film has attracted increasing interest in the last decades as a potential source of biomarkers of physiopathological states, due to its accessibility, moderate complexity, and responsiveness to ocular and systemic diseases. High‐performance liquid chromatography‐mass spectrometry (LC‐MS) has led to effective approaches to tear proteomics, despite the intrinsic limitations in sample amounts. This review focuses on the recent progress in strategy and technology, with an emphasis on the potential for personalized medicine. After an introduction on lacrimal‐film composition, examples of applications to biomarker discovery are discussed, comparing approaches based on pooled‐sample and single‐tear analysis. Then, the most critical steps of the experimental pipeline, that is, tear collection, sample fractionation, and LC‐MS implementation, are discussed with reference to proteome‐coverage optimization. Advantages and challenges of the alternative procedures are highlighted. Despite the still limited number of studies, tear quantitative proteomics, including single‐tear investigation, could offer unique contributions to the identification of low‐invasiveness, sustained‐accessibility biomarkers, and to the development of personalized approaches to therapy and diagnosis.

show abstract

Section: Biomarker Discovery In Ophthalmologymentioning

confidence: 99%

Mass spectrometry‐based tear proteomics for noninvasive biomarker discovery

Ponzini

Santambrogio

Palma

et al. 2021

Mass Spectrometry Reviews

View full text Add to dashboard Cite

show abstract

“…The angle is the junction between the iris and the cornea, where the trabecular meshwork drains the aqueous humor from the anterior chamber 47 .…”

Section: Glaucomamentioning

confidence: 99%

“…Nevertheless, about 50% of cases have normal intraocular pressure when diagnosed. After losing 30% of the RGCs, visual field damage is seen in perimetric tests 47 .…”

Section: Glaucomamentioning

confidence: 99%

“…Shorten eyes with a shallower anterior chamber are at higher risk. The disease can have a subacute or acute (after a sudden increase in intraocular pressure) or chronic (insidious and mostly asymptomatic) development 47 .…”

Section: Glaucomamentioning

confidence: 99%

“…Patients remain asymptomatic even as the disease progresses because the gradual loss is peripheral and asymmetric. This development generates compensation given by the other eye 47 .…”

Section: Glaucomamentioning

confidence: 99%

See 2 more Smart Citations

Monoclonal Antibodies: A Therapeutic Option for the Treatment of Ophthalmic Diseases of the Eye Posterior Segment

et al. 2022

View full text Add to dashboard Cite

The eye is an organ that allows us to observe the outside world. Pathologies of the eye's posterior segment, such as glaucoma, macular degeneration, diabetic retinopathy, uveitis, and retinoblastoma, cause vision loss. Traditional treatments consist of applying topical medications that do not penetrate properly or using high doses that generate adverse effects. Different laser surgeries stop the pathology's progression but do not allow visual improvement. So, an alternative is to use monoclonal antibodies, proteins produced by different processes that selectively bind to metabolites associated with diseases, reducing the adverse effects of traditional treatments and improving the application of the drug in the area. The two main molecular targets are TNF (adalimumab, infliximab, and certolizumab pegol) and VEGF (bevacizumab and ranibizumab); other possibilities are under investigation.

show abstract